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Background:  Left  atrial (LA)  enlargement  has  been  documented  to  occur  in hypertension  (HT),  and  has
been an  index  for evaluating  the diastolic  function  of  the  left  ventricle.  Enlargement  of the  LA  is one  of
the  vital  factors  that  induce  heart failure  and  atrial  ﬁbrillation  (AF)  in patients  with  HT.
Methods  and  subjects:  130 treated  hypertensive  patients  were  enrolled.  All  recruits  participated  in an
echocardiogram,  electrocardiogram,  a  routine  blood  examination  including  brain  natriuretic  peptide
(BNP),  and  physical  examinations.
Results:  Left  ventricular  mass  (LVM)  indexed  to  height2.7 had a signiﬁcant  positive  correlation  with  left
atrial  volume  index  (LAVI)  (p  <  0.0001),  as  well  as  natural  logarithm  BNP  (p  < 0.001).  Blood  pressure  levels
were not  associated  with  LAVI,  neither  body  mass  index  nor  age.  LAVI  had  a positive  correlation  with
factors  involving  the  left  ventricle  volume,  LVM,  and  right  ventricle  systolic  pressure  (RVSP)  (r  =  0.687,
p  < 0.0001).  The  parameters  of  LV  diastolic  function  were  positively  but  weakly  associated  with  LA size.
In the  subgroup  of  LAVI,  the  evidence  of paroxysmal  atrial ﬁbrillation  (PAF):  LAVI < 32  ml/m2 had  no PAF,
2whereas  the  incidence  of  PAF  was  7.5%,  11.4%,  and  15.2%,  respectively  in the  LAVI  >  32 ml/m group.  Of
anti-hypertension  drugs,  angiotensin-converting  enzyme  inhibitors  and  angiotensin  receptor  blockers
had  a  tendency  to reduce  LAVI;  however,  there  was  no  statistical  signiﬁcance  within  the  groups.
Conclusions:  Left ventricular  volume  and  mass  are  independent  factors  affecting  LAVI  in treated  HT. The
incidence of PAF  is associated  with  LA size.  In patients  with  treated  HT,  LA size  may  be a  useful  surrogate
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Left atrial (LA) enlargement often occurs in patients with hyper-
ension (HT) [1,2]. HT results in left ventricular (LV) hypertrophy
nd reduces LV diastolic function. LA volume is less inﬂuenced
y acute hemodynamic changes and reﬂects sub-acute or chronic
iastolic function. The increase in LA size and function occur in
arallel with the degree of LV diastolic dysfunction. It has been
stablished that LA volume is a sensitive marker for the sever-
ty of LV diastolic dysfunction [3,4]. Moreover, the occurrence of
aroxysmal atrial ﬁbrillation (PAF) in hypertensive subjects is asso-
iated with LA enlargement [5],  and the risk of developing AF is
ncreased by 1.5 times in patients with HT [5,6]. The Framingham
tudy revealed that a 5 mm increase in LA dimension produced a
9% increase in the incidence of AF [7].  AF is a major risk factor
∗ Corresponding author at: 89-1 Enya-cho, Izumo, 693-8501, Japan.
el.: +81 853 20 2249; fax: +81 853 20 2201.
E-mail address: kaz@med.shimane-u.ac.jp (K. Tanabe).
914-5087/$ – see front matter © 2012 Japanese College of Cardiology. Published by Else
ttp://dx.doi.org/10.1016/j.jjcc.2012.02.011ctiveness  of  medical  therapy  and  occurrence  of  AF.
anese  College  of  Cardiology.  Published  by  Elsevier  Ltd.  All rights  reserved.
for stroke and mortality. Therefore, it is crucial to identify patients
who have PAF in order to prevent subsequent thromboembolic
complications, especially in patients with HT. It is of importance
to assess the factors that affect LA volumes and the risk of AF in
patients with HT. Although the effect of HT on LA was  extensively
studied, few studies have addressed this in detail with relation
to treated HT, particularly in a population with well-controlled
blood pressure (BP). Accordingly, we  performed a study of patients
with HT and well-controlled BP who  had a comprehensive assess-
ment of echocardiography, especially for LA volume and its relative
factors.
Methods
SubjectsThis was  a retrospective cross-sectional study, which randomly
selected adult patients with HT history who  underwent a transtho-
racic echocardiogram for any indication at our institution from
vier Ltd. All rights reserved.
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Table 1
Clinical characteristics of the hypertensive population (n = 130).
Arrhythmias, % 22.3
Atrial enlargement, % 83.0
DM,  % 44.6
Hyperlipidemia, % 54.6
Current smoker, % 31.5
LV  diastolic function
Restricted ﬁlling pattern, % 3.0
Pseudonormal ﬁlling pattern, % 36.2
Medication
AECI or ARBs, % 18.5
Calcium antagonists, % 25.4
Both, % 44.6
Others, % 15.4
Deﬁning LA enlargement as the mean ± SD as calculated from
the LA volume indexed to BSA in this study, LA enlargement was
found in 83% of the hypertensive population in our study, 55.4%
was severe LA enlargement (≥40 ml/m2).
Table 2
Relationship of left atrial volume index to age, blood pressure, left ventricular mass,
and  parameters of left ventricular function (univariate regression analysis).
Variable Left atrial volume index
r B p
Age 0.076 0.117 NS
Gender 0.068 2.182 NS
Body mass index 0.061 −0.264 NS
Systolic blood pressure 0.071 0.061 NS
Diastolic blood pressure 0.107 −0.128 NS
Anti-hypertensive agents 0.091 0.085 NS
LV  ejection fraction 0.125 −0.265 NS
LV  mass 0.392 0.117 <0.0001
LV  mass indexed height2.7 0.513 0.564 <0.0001
LV  relative wall thickness 0.085 −15.28 NS
Inter-ventricular septal thickness 0.230 1.915 0.008
LV  posterior wall thickness 0.150 1.488 NS
LV  end-diastolic diameter 0.351 1.065 <0.0001
LV  end-systolic diameter 0.303 0.914 <0.0001
LV  end-diastolic volume 0.480 0.360 <0.0001
LV  end-systolic volume 0.340 0.456 0.0001
Peak E wave velocity 0.169 0.102 NS
E  wave deceleration time 0.072 −0.018 NS
Peak A wave velocity 0.024 0.018 NS34 Y. Chen et al. / Journal of 
anuary to December 2008. This study protocol was  approved by
he Ethical Committee of Shimane University.
Subjects consisted of 873 patients with HT from admission to the
linic in the Cardiology Department of Shimane University Hospi-
al. The data were corroborated from hospital records with their
reating physician. Patients who had previously documented sig-
iﬁcant valvular disease (more than mild valvular regurgitation or
tenosis), myocardial infarction, LV ejection fraction of <50%, and a
istory of AF, previous cardiac surgery, or implanted devices, and
ncomplete data were excluded. Of the 873 patients recruited, 743
f the patients were excluded based on the above exclusion crite-
ia. The ﬁnal HT population analyzed consisted of 130 patients with
inus rhythm and well-controlled BP (<140/90 mmHg) [8].  Mean
ge was 69.6 ± 10.1 years old, and the proportion of females was
9.2% (51/130). BP was checked, at the same day of the echocar-
iographic examination, and electrocardiogram and/or ambulatory
lectrocardiographic recording, routine blood samples including
rain natriuretic peptide (BNP) were performed within one week.
he normal value of BNP is <20 pg/ml, whereas >40 pg/ml is deﬁned
s abnormal.
tandard transthoracic echocardiographic study
Echocardiograms were performed according to established clin-
cal practice using 3 commercially available instruments, using
armonic 2.5–5 MHz  variable frequency phased-array transducers.
A and LV diameter by M-mode was measured in the parasternal
ong-axis view [9].  LV wall thickness was measured by M-mode
sing American Society of Echocardiography (ASE) criteria [10].
elative wall thickness was measured as 2× posterior wall thick-
ess in diastole divided by LV diastolic dimension, as an index of
he LV geometric pattern [11,12]. LV end-diastolic and end-systolic
olumes were determined from the apical 4- and 2-chamber views
sing the biplane method of discs [10]. LA volumes were measured
t ventricular systole just before the mitral valve opening. All vol-
mes were calculated from the apical 4- and 2-chamber zoomed
iews using the biplane method of discs [13,14]. LA volumes were
ndexed to body surface area (BSA). LA enlargement was deﬁned as
32 ml/m2.
LV diastolic function was determined using standard echocar-
iographic parameters including peak E velocity, peak A velocity,
/A ratio, and the deceleration time. The early diastolic velocity (Ea)
nd late diastolic velocity (Aa) of mitral annulus were measured by
oppler tissue imaging, by placing the sample volume at the septal
nnulus, recording at a sweep speed of 100 mm/s  and measured as
n average of 3 beats.
eft ventricular mass
The ASE-recommended area-length method was used to deter-
ine LV mass (LVM) [10]. LVM was indexed to allometric height2.7
15,16].  According to values from the Strong Heart Study [16], LVM
ubgroups were: group 1, normal LVM in women was classiﬁed as
44 g/m2.7 and in men  was ≤49 g/m2.7, group 2, mildly increased
VM in women was 45–50 g/m2.7 and in men  50–56 g/m2.7, group
, moderately increased LVM in women was 51–56 g/m2.7 and in
en  57–63 g/m2.7, and group 4, severely increased LVM in women
as ≥57 g/m2.7 and in men  ≥64 g/m2.7.
tatistical analysis
All values are expressed as mean ± SD. Plasma concentrations
f BNP did not follow a Gaussian distribution and then were trans-
ormed with a natural logarithm preceding statistical analysis.
inear regression was used to examine the correlation between
he clinical factors and LA size. Subgroups of different drugs wereDM,  diabetes mellitus; LV, left ventricular; ACEI, angiotensin-converting enzyme
inhibitors; ARBs, angiotensin receptor antagonist; Others, -blockers or diuretics;
Both, ACEI and/or ARBs and calcium antagonists.
analyzed using one-way ANOVA. The correlation between 2 vari-
ables was assessed by the Pearson rank correlation coefﬁcient.
Univariate and multivariate regression analysis was used to exam-
ine independent predictors of an increased LA size. Data were
analyzed using SPSS version 11.5 (SPSS Inc., Chicago, IL, USA) and
Graphpad Prism 5.0 (Graphpad, La Jolla, CA, USA), p < 0.05 was  con-
sidered statistically signiﬁcant.
Results
Clinical characteristics of the HT group are given in Table 1.
In our study, 80% of the population was  on ≤3 antihyperten-
sive medications, and their BP was well controlled (systolic BP,
135.2 ± 18.5 mmHg, diastolic BP, 73.9 ± 13.2 mmHg). The mean val-
ues for clinical and echocardiographic parameters for the patients
are listed in Tables 1–4.
LA volume and factors inﬂuencing LA enlargementA  wave duration 0.163 0.022 NS
E/A  ratio 0.200 11.240 0.023
RVSP 0.372 1.048 <0.0001
LV, left ventricular; RVSP, right ventricular systolic pressure.
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Table  3
Anti-hypertensive effect on left atrial size.
Group Mean ± SD Std. error 95% CI
ACEI and/or ARBs 38.61 ± 14.61 2.469 33.60–43.63
Others  (beta-blocker or diuretic) 43.00 ± 9.487 3.000 36.21–49.79
Both  Ca2+-antagonist and ACEI and/or ARBs 45.64 ± 13.99 1.672 42.30–48.97
Ca2+-antagonist 46.78 ± 20.58 3.529 39.60–53.95
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.
Table 4
General characteristics of study patients divided according to left ventricular mass indexed to height2.7 (n = 130).
Parameters Group 1 (n = 50) Group 2 (n = 31) Group 3 (n = 13) Group 4 (n = 36)
Age (years) 69.73 ± 5.53 69.91 ± 11.34 68.29 ± 9.64#,† 69.54 ± 9.80
BMI  (kg/m2) 23.25 ± 3.05 23.03 ± 2.86 25.81 ± 2.22#,† 24.34 ± 4.15 ,‡
SBP (mmHg) 136.42 ± 17.34 130.38 ± 15.83* 134.09 ± ± 15.81#,† 138.86 ± 20.55 ,§ ,‡
DBP (mmHg) 75.54 ± 13.31 72.52 ± 11.40* 77.63 ± 11.63#,† 70.71 ± 13.75 ,§ ,‡
LnBNP 3.47 ± 1.17 3.59 ± ± 1.14* 4.10 ± 1.22#,† 4.57 ± 1.17 ,§ ,‡
LAVI (ml/m2) 39.34 ± 10.00 47.63 ± 15.51* 53.14 ± 21.06#,† 60.34 ± 19.09 ,§ ,‡
LAD (mm)  40.17 ± 5.03 41.25 ± 4.22* 45.10 ± 8.61#,† 45.26 ± 5.41§ ,‡
E (cm/s) 68.05 ± 38.72 60.90 ± 16.63* 59.4 ± 16.19# 69.57 ± 20.15‡
A (cm/s) 81.54 ± 22.03 84.79 ± 19.38* 76.52 ± 18.02#,† 88.38 ± 22.96 ,§ ,‡
E/A 0.826 ± 0.297 0.738 ± 0.196* 0.784 ± 0.240#,† 0.836 ± 0.362 ,‡
DT (s) 261.92 ± 78.42 262.50 ± 64.04 228.04 ± 33.32#,† 245.08 ± 51.59 ,§ ,‡
Ea (cm/s) 5.41 ± 1.72 5.51 ± 1.60 5.41 ± 2.73 5.23 ± 2.04 ,§ ,‡
Aa (cm/s) 9.70 ± 2.85 8.87 ± 1.78* 7.92 ± 2.04#,† 8.07 ± 2.14§ ,‡
Ea/Aa 0.58 ± 0.19 0.64 ± 0.18* 0.63 ± 0.29# 0.67 ± 0.33 ,§ ,‡
E/Ea 17.06 ± 7.14 11.97 ± 5.20* 12.68 ± 4.15# 15.18 ± 6.76 ,§ ,‡
RVSP 33.60 ± 4.55 34.16 ± 4.93* 35.45 ± 3.84#,† 36.83 ± 6.66 ,§ ,‡
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; LnBNP, natural logarithm of brain natriuretic peptide; LAVI, left atrial volume index; LAD,
left  anterior descending artery; DT, deceleration time; RVSP, right ventricular systolic pressure.
* p < 0.01, between group 1 and 2.
# p < 0.01, between group 1 and 3.
§ p < 0.01, between group 1 and 4.
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no inﬂuence on LA size, among the inter-subgroups of medications
(p > 0.05). However, the group taking calcium-channel antagonists
seems to have had a larger LA size (Table 3 and Fig. 2).† p < 0.01, between group 2 and 3.
‡ p < 0.01, between group 2 and 4.
 p < 0.01, between group 3 and 4.
To determine the independent correlates of LAVI, univariate and
ultivariate regression analyses were performed. Input variables
ncluded age, gender, antihypertensive drugs, systolic and diastolic
P, body mass index, LVM, LV geometry (relative wall thick-
ess), parameters of diastolic function (peak E, Ea velocity), and
ight ventricular systolic pressure (RVSP). By univariate analysis, a
ositive correlation was noted between LAV and LV end-systolic
olume (r = 0.340), LV end-diastolic volume (LVEDV) (r = 0.480),
VM (r = 0.513), RVSP (r = 0.372), inter-ventricular septal thickness
r = 0.230), LV end diastolic diameter (r = 0.351), and LV end-systolic
iameter (r = 0.303) (p < 0.0001, for all). Neither BP, nor the use of
ntihypertensive medications inﬂuenced LA geometry. The geom-
try pattern of LV (relative wall thickness) was not associated with
A size. LAVI was weakly correlated with parameters of LV diastolic
unction (Table 2). When the univariate predictors were entered
nto a multivariate analysis, the only independent correlates of
ncreased LA size included LVM indexed to height2.7 (p < 0.0001),
V end-diastolic volume (p < 0.0001), and RVSP (p < 0.0001). Using a
est-ﬁt model, LAVI = 0.628 + 0.246 LVEDV + 0.235 LVMH2.7 + 0.410
VSP (adjusted r2 = 0.407).
ight ventricle systolic pressure and LVM
In our population, LVM-height2.7 had a signiﬁcant correlation
ith RVSP (p = 0.0013). Furthermore, there was a positive correla-
ion between RVSP and E/A (r = 0.26, p = 0.0063).A size and biomarkers
Plasma BNP exceeded the upper limit of the correspond-
ng normal range in 94 (72.3%) subjects of the hypertensivepopulations. In linear regression, concentration of BNP had a sig-
niﬁcant positive correlation with LA size (r = 0.480, p < 0.0001)
(Fig. 1).
Anti-hypertensive effect on LA size
In present study, the use of anti-hypertensive medications hadFig. 1. The correlation between left atrial volume index (LAVI) and natural logarithm
of  brain natriuretic peptide (LnBNP).
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Fig. 2. Effect of anti-hypertensive agents on left atrial volume index (LAVI). Others,
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ciuretic and beta-blockers; ACEI, angiotensin-converting enzyme inhibitors; ARBs,
ngiotensin receptor blockers; Ca-anti, calcium antagonist; Both, ACEI, ARBs, and a
alcium antagonist.
AVI and atrial arrhythmias
In subgroups of LAVI according to quartile (1, <32 ml/m2; 2,
2–41 ml/m2; 3, 41–51 ml/m2; 4, ≥51 ml/m2), 4.5% in group 1 had
trial arrhythmias, but no PAF. In group 2, there were 22.5% of atrial
rrhythmias, of which 7.5% were PAF; there were 28.6% and 27.3% of
trial arrhythmias in groups 3 and 4, respectively. The incidence of
AF was 11.4% and 15.2% in groups 3 and 4, respectively. However,
he difference was not statistically signiﬁcant (Fig. 3).
A volumes and LV hypertrophy
Hypertensive subjects were further divided into 4 groups on the
asis of LVM as previously described. LA indexed volumes were sig-
iﬁcantly increased in group 4 compared with the other 2 groups,
ut those of groups 3 and 4 were not statistically signiﬁcant (Fig. 4).
V mass and diastolic function
In our group, 36.2% had a pseudo-normalized ﬁlling pattern or
mpaired relaxation with normal or near-normal ﬁlling pressure,
nd 60.8% had a normal or near normal ﬁlling pattern, the remain-
er was 3.0%. In the subgroup based on LVM, LAVI, peak E, peak
, deceleration time, E/Ea, Aa, Ea/Aa and RVSP were signiﬁcantly
ifferent within the 4 groups previously described (Table 4).
iscussionIn our population with HT, almost all of them (83%) had an
nlarged LA size. We  have demonstrated that LV volume, including
iastolic volume and systolic volume, was signiﬁcantly associated
ith LA size. The parameters of LV diastolic function had positive
ig. 3. The evidence of atrial arrhythmias in groups according to left atrial volume
ndex (LAVI). Paf, paroxysmal atrial ﬁbrillation; SPVC, supraventricular premature
ontraction.Fig. 4. The difference in left atrial volume index (LAVI) in subgroups of left ventric-
ular mass indexed to height2.7 (LVMH2.7).
but weak correlations with LA size in treated HT. Correspondingly,
there were 39.2% patients with grade 2 or greater of LV diastolic
dysfunction, whereas LA enlargement was found in 83% of the pop-
ulation with HT in our study. LA morphology changes may have
emerged ahead of LV diastolic dysfunction. Interestingly, LV geom-
etry itself had no inﬂuence on LA size. However, in our study, the
patients with LV hypertrophy showed more advanced diastolic
dysfunction according to the mitral inﬂow indices. Whatever LV
volume or diastolic function, LA after-load increases may  have an
effect on LA size in patients with HT.
Aging and diastolic properties
Age-related changes in LV diastolic properties are well recog-
nized with a decrease in early diastolic ﬁlling and compensatory
increase in late ﬁlling [17,18]. In our study, LV volume and mass
signiﬁcantly had an inﬂuence on LA size. In the general population,
the prevalence of LA size increases with aging [17,19,20].  However,
we demonstrated that normal aging does not result in a signiﬁcant
increase in LA size. HT results in an increase in overall LA size due to
further reduction in LV diastolic function due to HT over and above
normal age-related changes.
Effect of HT and anti-hypertensive medications on LA size
In treated patients with HT, BP is not a signiﬁcant factor that
has an effect on LA size anymore. However, 83% of patients had an
enlarged LA size in our population. Salako et al. [21] showed that
cardiac structural changes do remain despite anti-hypertensive
therapy. In our study, it was  not possible to keep LA size nor-
malized despite anti-hypertensive medication administration and
well-controlled BP. However, Gerdts et al. [22] reported that LA size
reduction may  reduce the incidence of cardiac events during anti-
hypertensive treatment. Regarding anti-hypertension medications,
angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin
receptor blockers (ARBs) were reported to alleviate LA ﬁbrosis and
size, and in our groups, even though not statistically signiﬁcant,
the group using ACEIs or ARBs seemed to have had a smaller LA
size than groups using other medications, including -blockers and
diuretics. The subgroup taking calcium-channel antagonists alone
appeared to have had a larger LA volume than the subjects that
used AECIs and/or ARBs combined with calcium-channel antago-
nists simultaneously. Compared with calcium-channel antagonists,
ACEIs or ARBs may be more useful to reduce LA volume.
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The renin–angiotensin system is involved in myocardial ﬁbrosis
n hypertensive heart disease, congestive heart failure, myocar-
ial infarction, and cardiomyopathy [23,24]. ACEIs may  reduce
brosis and improve AF indices in experimental models [25–27].
n addition, Heckbert et al. [28] reported that single-drug use
f ACEIs/ARBs was associated with a lower AF risk in a general
ypertensive population without heart failure. ARBs may  also be a
easonable approach to prevent or reverse angiotensin II-induced
trial structural remodeling [29,30].  This may  partly explain why
he group taking ACEIs and/or ACEIs had a smaller LA volume than
he other groups. -Blockers and diuretics could improve LV dias-
olic function and decreasing the preload of heart may  decrease LA
olume.
Tanabe et al. [31] reported that there was no difference between
roups taking ACEIs or ARBs and groups on other anti-hypertensive
edications in the occurrence of cardiac events, whereas ideal BP
ontrol could decrease the events (including the occurrence of PAF)
nd reduce LA size signiﬁcantly. This indicated that well-controlled
P itself may  be essentially more important for reducing LA volume.
mpact of increased LA size in HT
Population-based studies have found that LA enlargement
ccurs in 22% of patients with HT when using LA diameter indexed
o BSA, and 27% when LA volume is indexed to BSA [32]. There was
 higher portion of LA enlargement in our population, 83% of all
ubjects were found to have LA enlargement when LA volume was
ndexed to BSA.
Increased LA size is associated with the increased occurrence
f AF [33,34]. HT is associated with an increased risk of AF, and
eads to a pronounced increase in morbidity and mortality. In
ur study, even though not statistically signiﬁcant, there had
een an increased tendency of AF with LA size, especially LAVI
41 ml/m2. Determinants of LA enlargement predisposing to AF
emain unsolved. LA size might reﬂect marked hemodynamic atrial
verload in a speciﬁc phase during the course of a chronic disease,
uch as HT. Atrial stretch and enlargement of the chamber lead to
emodeling of the structure, physiologic properties, and electrical
ilieu of the LA, culminating in the development of AF. Interest-
ngly, some patients had a large LA size, but they can keep sinus
hythm. The factors concerning the occurrence of AF may  be more
omplicated, and the mechanism is still unknown. LAV may  be an
mportant prognostic marker for the occurrence of AF in popula-
ions with HT.
ight ventricle systolic pressure and LA size
In our population, RVSP had a signiﬁcant correlation with LA
ize. RVSP based on the estimated ﬂow of the tricuspid regurgi-
ation jet has been established as a surrogate for the pulmonary
rtery systolic pressure. Regardless of ejection fraction, elevation in
V ﬁlling pressure leads to passive pulmonary venous congestion
nd postcapillary pulmonary HT [35]. LA volume is a barometer
f LV ﬁlling pressure and reﬂects the burden of diastolic dysfunc-
ion. This may  explain why RVSP had a correlation with LA size.
ecause the majority of individuals in the community with HT
re in a preclinical phase of heart failure [36], methods to quan-
ify the risk of progression to symptomatic heart failure would be
linically useful. Recently, Ferlinz [37] reported that RV diastolic
nd systolic function deteriorates in response to slightly increased
ystemic BP. The process paralleled homologous changes at the
V side and was driven by interventricular septum remodeling,
erhaps as a reﬂection of its role in RV function and biventricu-
ar interdependence. Further research should be performed in the
uture.
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Brain natriuretic peptide and LA size
BNP is increased in acute or chronic heart failure, secondary to
either systolic or diastolic dysfunction [38–41].  LV diastolic dys-
function is related to LA enlargement, which had been considered
as chronic LA dysfunction and has been correlated well with the
duration or severity of diastolic heart failure [42]. We reported that
in HT with cardiac hypertrophy, BNP levels are elevated and such
sources are the atrium rather than the ventricle, and also demon-
strated that in lone AF the source of BNP is the atrium [43,44]. In
our population, LA enlargement was  found in 83%. Correspondingly,
the exceeding BNP cut-off was  found in 72.3% of all patients. In
hypertensive patients, BNP may  be regarded as a biomarker for LA
enlargement or elevated LA pressure.
Study limitations
First, this was  a retrospective study. To clarify whether the
present index can predict future AF development or complications,
further research must provide longitudinal assessments. Second,
it is difﬁcult to distinguish whether the impaired atrial function
was attributed to LA remodeling or showed a recovery process
after spontaneous conversion of AF. This issue does not concern
the diagnosis of PAF, but it may  affect the value for detecting PAF.
Conclusion
In patients with treated HT, LV end-diastolic volume and LVM
may  be pivotal for LA size enlargement. The incidence of PAF is
associated with LA size. In patients with HT, LA size may  be a use-
ful surrogate marker for monitoring the effectiveness of medical
therapy and occurrence of AF.
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